EP 4380625 A1 20240612 - ANTIBODY-DRUG CONJUGATES
Title (en)
ANTIBODY-DRUG CONJUGATES
Title (de)
ANTIKÖRPER-WIRKSTOFF-KONJUGATE
Title (fr)
CONJUGUÉS ANTICORPS-MÉDICAMENT
Publication
Application
Priority
- FR 2108537 A 20210805
- FR 2022051554 W 20220804
Abstract (en)
[origin: CA3227955A1] The invention relates to a conjugate containing a) an antibody or fragment of an antibody, and b) a specific protease for the immunoglobulin G (IgG) hinge region. The invention also relates to a composition comprising at least one such conjugate, as well as to the use of this conjugate as a drug, in particular for the treatment of a disease caused by autoantibodies.
IPC 8 full level
A61K 47/68 (2017.01); A61K 38/43 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01)
CPC (source: EP US)
A61K 47/6815 (2017.08 - EP US); A61K 47/6855 (2017.08 - US); A61K 47/6889 (2017.08 - EP US); A61P 37/02 (2018.01 - EP); C07K 16/32 (2013.01 - EP US); C12N 9/52 (2013.01 - EP US); C07K 2317/55 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
FR 3125965 A1 20230210; FR 3125965 B1 20240621; CA 3227955 A1 20230209; CN 118251239 A 20240625; EP 4380625 A1 20240612; JP 2024530025 A 20240814; US 2024342301 A1 20241017; WO 2023012437 A1 20230209
DOCDB simple family (application)
FR 2108537 A 20210805; CA 3227955 A 20220804; CN 202280065825 A 20220804; EP 22760765 A 20220804; FR 2022051554 W 20220804; JP 2024506901 A 20220804; US 202218294636 A 20220804